Tripla negatív emlőrák: vizsgálatok itt: Kanada
23 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Where
- Chicoutimi, Edmonton, Montreal, Oshawa, Québec, Saskatoon, Toronto
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06841354 · EU 2024-516834-36-00 - 3. fázisTaking peopleA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Where
- Barrie, Greater Sudbury, Montreal, Oshawa, Ottawa, Québec, Regina, Sault Ste. Marie, Sherbrooke, St. John's, Surrey, Toronto, Trois-Rivières, Vancouver
- Életkor
- 18 év and over
- People
- 2400 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06966700 · EU 2024-520190-12-00 - 3. fázisTaking peopleSacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Where
- Calgary, Edmonton, Greenfield Park, Halifax, Hamilton, Kingston, Moncton, Montreal, Newmarket, Ottawa, Rimouski, Toronto, Trois-Rivières, Vancouver, Winnipeg
- Életkor
- 18 év and over
- People
- 1530 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06393374 · EU 2023-504962-52-00 - 3. fázisTaking peopleROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Where
- Québec, Toronto
- Életkor
- 18 év and over
- People
- 558 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07173751 · EU 2025-521884-12-00 - 1/2. fázisTaking peopleEnhancing ICB Efficacy Through IL-1 Inhibition in TNBC
- Where
- Toronto
- Életkor
- 18 év and over
- People
- 60
- Run by
- University Health Network, Toronto
See details and how to joinNCT07698106 - 1. fázisTaking peopleGCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
- Where
- Calgary, Montreal, Ottawa, Toronto
- Életkor
- 15 év and over
- People
- 30
- Run by
- Canadian Cancer Trials Group
See details and how to joinNCT07297667 - 1. fázisTaking peoplePhase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
- Where
- Montreal
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07261631 - 2. fázisTaking peopleFirst-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.
- Where
- Vancouver
- Életkor
- 18 év and over
- People
- 24
- Run by
- Nathalie Levasseur
See details and how to joinNCT07299409 - 3. fázisTaking peopleA Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Where
- Barrie, Greenfield Park, Hamilton, Montreal, Québec, Regina, Saskatoon, Toronto
- Életkor
- 18 év and over
- People
- 625 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06103864 - 1/2. fázisTaking peopleA Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Where
- Edmonton, Montreal, Newmarket, Ottawa
- Életkor
- 18 év and over
- People
- 416 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06618287 - 1/2. fázisTaking peopleFirst in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- Where
- Toronto
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- Gilead Sciences
See details and how to joinNCT06657222 · EU 2025-522517-35-00 - 1/2. fázisTaking peopleA Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Where
- Edmonton, Hamilton, Montreal, Ottawa, Toronto, Vancouver
- Életkor
- 18 év and over
- People
- 1109 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT04895709 - 2/3. fázisTaking peopleA Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Where
- Kelowna, Montreal, Ottawa, Saint-Charles-Borromée, Sherbrooke, Victoria
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06926868 · EU 2024-519871-24-00 - 3. fázisTaking peoplePembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
- Where
- Cambridge, Kelowna, Kingston, London, Montreal, Ottawa, Québec, Regina, Saint John, Saskatoon, Toronto, Trois-Rivières, Vancouver
- Életkor
- 18 év and over
- People
- 1295 worldwide
- Run by
- Alliance for Clinical Trials in Oncology
See details and how to joinNCT05812807 - 1. fázisTaking peoplePhase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Where
- Montreal, Toronto
- Életkor
- 18 év to 100 év
- People
- 162 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06562192 - 1. fázisTaking peopleA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Where
- Montreal, Toronto
- Életkor
- 18 év and over
- People
- 714 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00 - 1. fázisTaking peopleStudy to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Where
- Calgary, Montreal, Toronto
- Életkor
- 18 év and over
- People
- 694 worldwide
- Run by
- AbbVie
See details and how to joinNCT05005403 - 1. fázisTaking peoplePQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
- Where
- Toronto
- Életkor
- 18 év and over
- People
- 80 worldwide
- Run by
- ProteinQure Inc.
See details and how to joinNCT07190469 - 2. fázisTaking peopleNeoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer
- Where
- London
- Életkor
- 18 év and over
- People
- 40
- Run by
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
See details and how to joinNCT07188246 - 1/2. fázisNot yet taking people in KanadaFMT in Triple Negative Breast Cancer Guided by ctDNA
- Where
- London, Montreal, Ottawa
- Életkor
- 18 év and over
- People
- 125
- Run by
- Jewish General Hospital
See details and how to joinNCT07292142 - 2. fázisNot yet taking people in KanadaTemozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)
- Where
- Calgary
- Életkor
- 18 év and over
- People
- 40
- Run by
- AHS Cancer Control Alberta
See details and how to joinNCT05128734 - No phaseTaking peopleTRIple Negative Breast Cancer Markers In Liquid Biopsies Using Artificial Intelligence
- Where
- London, Montreal, Ottawa
- Életkor
- 18 év and over
- People
- 130
- Run by
- Jewish General Hospital
See details and how to joinNCT04874064 - 2. fázisTaking peopleTriple Negative Breast Cancer and Celecoxib. Pilot Study
- Where
- Sherbrooke
- Életkor
- 18 év and over
- People
- 30
- Run by
- Université de Sherbrooke
See details and how to joinNCT07104266